Tiotropium + Aclidinium
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Disease, Chronic Obstructive
Conditions
Pulmonary Disease, Chronic Obstructive
Trial Timeline
Feb 1, 2014 → Jul 1, 2015
NCT ID
NCT02039050About Tiotropium + Aclidinium
Tiotropium + Aclidinium is a approved stage product being developed by Almirall for Pulmonary Disease, Chronic Obstructive. The current trial status is completed. This product is registered under clinical trial identifier NCT02039050. Target conditions include Pulmonary Disease, Chronic Obstructive.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02039050 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Disease, Chronic Obstructive